T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma
Interventions: DRUG: Palbociclib|DRUG: T-DM1
Sponsor: University of Arizona
Collaborators: Pfizer